EUCTR2007-004120-21-DE
Active, not recruiting
Not Applicable
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7® Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastatic Melanoma - Allovectin-7® Immunotherapy for Metastatic Melanoma (A.I.M.M)
Vical Incorporated0 sites375 target enrollmentSeptember 17, 2007
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Vical Incorporated
- Enrollment
- 375
- Status
- Active, not recruiting
- Last Updated
- 12 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •\- Able and willing to provide informed consent and sign the informed consent form
- •\- Age 18 or more years
- •\- ECOG performance status of 0 or 1
- •\- Histologically confirmed recurrent metastatic melanoma, which may have received primary surgical resection, adjuvant therapy, and/or biotherapy
- •\- At least one injectable lesion (cutaneous, subcutaneous, or nodal lesion) \=1 cm2 and \=25 cm2\. Lesions between 25 cm2 and 100 cm2 are not injected but may be followed as target lesions
- •\- LDH within normal limits
- •\- Serum creatinine \= 2\.0 mg/dL
- •\- Platelet count 100,000/mm3 or more
- •\- White blood cell count 2500/mm3 or more
- •\- Male and female subjects of child bearing potential must agree to use an effective method of contraception
Exclusion Criteria
- •\- Prior cytotoxic chemotherapy for malignant melanoma
- •\- Prior Allovectin\-7® injection(s)
- •\- Any lesion 100 cm2 or more
- •\- History of visceral metastasis, M1c, other than lung (M1b not excluded)
- •\- Surgery as a curative option
- •\- Radiation therapy, immunosuppressive therapy or biologic therapy within four weeks prior to trial entry
- •\- Major surgery within two weeks prior to trial entry
- •\- Known positive HIV serology
- •\- Other malignancy not currently in remission or unlikely to have been cured with prior therapy (except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or low grade prostate cancer)
- •\- Concurrent immunosuppressive therapy, anticancer therapy or investigational treatment
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with2 mg Intralesional Allovectin-7® Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastatic Melanoma - Allovectin-7® Immunotherapy for Metastatic Melanoma (A.I.M.M)Recurrent metastatic melanomaMedDRA version: 9.1Level: LLTClassification code 10027481Term: Metastatic melanomaEUCTR2007-004120-21-BEVical Incorporated375
Active, not recruiting
Not Applicable
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with2 mg Intralesional Allovectin-7® Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastatic Melanoma - Allovectin-7® Immunotherapy for Metastatic Melanoma (A.I.M.M)EUCTR2007-004120-21-NLVical Incorporated375
Active, not recruiting
Not Applicable
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Treatment with 2 mg Intralesional Allovectin-7® Compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in Subjects with Recurrent Metastatic Melanoma - Allovectin-7® Immunotherapy for Metastatic Melanoma (A.I.M.M)EUCTR2007-004120-21-PLVical Incorporated375
Completed
Phase 3
A Phase 3 Clinical Trial to evaluate the safety and efficacy of treatment with 2 mg intralesional Allovectin-7® compared to Dacarbazine (DTIC) or Temozolomide (TMZ) in subjects with recurrent metastatic melanomaNL-OMON31643Vical Incorporated15
Active, not recruiting
Phase 1
A clinical trial to assess the safety and efficacy of MK-1293 compared to Lantus? in treatment of Diabetes Mellitus.Type 1 Diabetes MellitusMedDRA version: 16.1Level: PTClassification code 10067584Term: Type 1 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]EUCTR2011-003971-12-ESMerck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.500